A Study to Compare Conventional Heart Echo Measurements with Newer 2 and 3 Dimensional Measurements of Mechanical Heart Strain after Trastuzumab Infusion


About this study

The purpose of this study is to compare conventional assessment of systolic ventricular function on a 2D heart echo with an assessment of more immediate changes in heart mechanics using 2D and 3D measurements of deformation and strain in patients undergoing infusion of Trastuzumab for breast cancer.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Histological diagnosis of breast cancer and undergoing trastuzumab treatment
    • Her2 gene amplification (2+, 3+) by immunohistochemical analysis (IHC) or fluorescence in situ hybridization (FISH)
    • Stage I-II-III-IV

Exclusion Criteria 

  • Inadequate image quality
  • Irregular R-R Interval
  • Age <18 years
  • Previous cardiovascular disease (coronary artery disease, congestive heart failure, cardiomyopathy)
  • Moderate or severe valvular stenosis or regurgitation
  • Uncontrolled hypertension
  • Moderate to severe pericardial effusion or pericardial metastasis
  • CNS metastasis
  • Previous trastuzumab treatment

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Hector Villarraga, M.D.

Closed for enrollment

Contact information:

Katherine Tilkes

(507) 538-1281


More information


Publications are currently not available

Mayo Clinic Footer